Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2

Franck Touret; Jean-Selim Driouich; Maxime Cochin; Paul Remy Petit; Magali Gilles; Karine Barthelemy; Gregory Moureau; Francois-Xavier MAHON; Denis Malvy; Caroline Solas; Xavier de Lamballerie; Antoine Nougairede.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-386904

Documentos relacionados

  1. Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2.
  2. Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2.
  3. A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection.
  4. Lithium salts as a treatment for COVID-19: Pre-clinical outcomes.
  5. [New Analogues of Uridine as Possible Anti-Viral Agents Specific to SARS-CoV-2].
  6. Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates.
  7. Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19.
  8. Mechanistic insights of key host proteins and potential repurposed inhibitors regulating SARS-CoV-2 pathway.
  9. Identification of herbal teas and their compounds eliciting antiviral activity against SARS-CoV-2 in vitro.
  10. Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro.